These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1413811)

  • 1. [Vasoactive drugs with an effect on the prostaglandin system].
    Pallapies D
    Wien Klin Wochenschr; 1992; 104(17):521-5. PubMed ID: 1413811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
    Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function.
    Yarger WE; Schocken DD; Harris RH
    J Clin Invest; 1980 Feb; 65(2):400-12. PubMed ID: 7356687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostacyclin, thromboxane A2, and hypertension.
    Zhao WG; Richardson JS
    Clin Invest Med; 1990 Dec; 13(6):343-52. PubMed ID: 2078914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacology of anti-platelet agents].
    Lecompte T; Kher A; Gaillard JL; Samama M
    J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer blood-borne metastasis and platelets].
    Tanaka K; Fukumoto S
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2453-9. PubMed ID: 6391385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets.
    Schildknecht S; van der Loo B; Weber K; Tiefenthaler K; Daiber A; Bachschmid MM
    Free Radic Biol Med; 2008 Aug; 45(4):512-20. PubMed ID: 18514074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.
    Darius H; Ahland B; Rücker W; Klaus W; Peskar BA; Schrör K
    J Cardiovasc Pharmacol; 1984; 6(1):115-21. PubMed ID: 6199592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prostacyclin and thromboxane A2 in the regulation of platelet behaviour.
    Moncada S
    Mater Med Pol; 1980; 12(3):207-12. PubMed ID: 7019591
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prostanoids and hemostasis].
    Lecompte T; Mamas S
    Therapie; 1991; 46(3):227-30. PubMed ID: 1792656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.
    Puscas I; Coltau M; Baican M; Pasca R; Domuta G; Hecht A
    Drugs Exp Clin Res; 2001; 27(2):53-60. PubMed ID: 11392054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane.
    Fabi F; Argiolas L; Ruvolo G; del Basso P
    Br J Pharmacol; 1998 May; 124(1):101-10. PubMed ID: 9630349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet aggregating response to platelet activating factor participates in activation of the 12-lipoxygenase pathway in platelets from rabbits.
    Michibayashi T
    Int Angiol; 2002 Sep; 21(3):260-7. PubMed ID: 12384648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thromboxane A2-PGI2 balance regulation and activating blood circulation and relieving blood stasis].
    Wu YS
    Zhong Xi Yi Jie He Za Zhi; 1986 Feb; 6(2):121-4. PubMed ID: 2942288
    [No Abstract]   [Full Text] [Related]  

  • 20. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.